Gilead & Remdesivir mentioned by a guest analyst on Fox Business just minutes ago. What was mentioned? 25 BILLION of cash on hand, interest in acquiring promising biotech properties, and issues with Remdesivir. I bet they aren't watching any active drug trials. That would be such a waste of time for them because they can just wait for "the market" to guide their business decisions.